Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute and two-week effects of Spiolto Respimat on cardiac and pulmonary function in hyperinflated COPD
2019-002256-16Phase 4Terminated
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tiotropium + olodaterol, tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Fraunhofer-Gesellschaft. Started Sep 2019; status: terminated.
02
Drugs
tiotropium + olodateroltiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-002256-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002256-16.